• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用重组 UGT 预测葡萄糖醛酸化介导的药物清除率时,相对活性与相对表达因子(RAF 与 REF)的比较。

Comparison of Relative Activity versus Relative Expression Factors (RAF versus REF) in Predicting Glucuronidation Mediated Drug Clearance Using Recombinant UGTs.

机构信息

Department of Pharmaceutical Sciences, Washington State University (WSU), Spokane, WA, 99202, USA.

Novartis Institutes for BioMedical Research, Inc, Cambridge, MA, USA.

出版信息

Pharm Res. 2024 Aug;41(8):1621-1630. doi: 10.1007/s11095-024-03750-x. Epub 2024 Aug 6.

DOI:10.1007/s11095-024-03750-x
PMID:39107514
Abstract

PURPOSE

Predicting the quantitative fraction of glucuronidation (f) by individual UDP-glucuronosyltransferase enzymes (UGTs) is challenging due to the lack of selective inhibitors and inconsistent activity of recombinant UGT systems (rUGTs). Our study compares the relative expression versus activity factors (REF versus RAF) to predict f based on rUGT data to human liver and intestinal microsomes (HLM and HIM).

METHODS

REF scalars were derived from a previous in-house proteomics study for eleven UGT enzymes (UGT1A1, UGT1A3, UGT1A4, UGT1A6, UGT1A9, UGT1A10, UGT2B4, UGT2B7, UGT2B10, UGT2B15, and UGT2B17), whereas RAF was calculated by measuring activities in rUGTs to microsomes of selective UGT probe substrates. Protein-normalized activity factor (pnAF) values were generated after correcting activity of individual UGTs to their corresponding protein abundance. The utility of REF and RAF in predicting f was assessed for three UGT substrates-diclofenac, vorinostat, and raltegravir.

RESULTS

The REF values ranged from 0.02 to 1.75, RAF based on activity obtained in rUGTs to HLM/HIM were from 0.1 to 274. pnAF values were ~ 5 to 80-fold, except for UGT2B4 and UGT2B15, where pnAF was ~ 180 and > 1000, respectively. The results revealed confounding effect of differential specific activities (per pmol) of rUGTs in f prediction.

CONCLUSION

The data suggest that the activity of UGT enzymes was significantly lower when compared to their activity in microsomes at the same absolute protein amount (pmol). Collectively, results of this study demonstrate poor and variable specific activity of different rUGTs (per pmol protein), as determined by pnAF values, which should be considered in f scaling.

摘要

目的

由于缺乏选择性抑制剂以及重组 UGT 系统(rUGTs)的活性不一致,预测个体 UDP-葡糖醛酸基转移酶(UGTs)的葡糖醛酸化定量分数(f)具有挑战性。我们的研究比较了相对表达与活性因子(REF 与 RAF),以根据 rUGT 数据预测人肝和肠微粒体(HLM 和 HIM)中的 f。

方法

11 种 UGT 酶(UGT1A1、UGT1A3、UGT1A4、UGT1A6、UGT1A9、UGT1A10、UGT2B4、UGT2B7、UGT2B10、UGT2B15 和 UGT2B17)的 REF 标度源自之前的内部蛋白质组学研究,而 RAF 则通过测量 rUGTs 对选择性 UGT 探针底物的微粒体的活性来计算。在将个体 UGT 的活性校正至其相应的蛋白质丰度后,生成蛋白归一化活性因子(pnAF)值。评估了 REF 和 RAF 在预测三种 UGT 底物(双氯芬酸、伏立诺他和雷特格韦)的 f 中的作用。

结果

REF 值范围为 0.02 至 1.75,基于 rUGTs 在 HLM/HIM 中的活性获得的 RAF 值为 0.1 至 274。pnAF 值为 5 至 80 倍,UGT2B4 和 UGT2B15 除外,其 pnAF 值分别约为 180 和>1000。结果表明,rUGTs 之间的差异特异性活性(每 pmol)对 f 预测存在混杂效应。

结论

数据表明,与在相同绝对蛋白质量(pmol)下的微粒体中的活性相比,UGT 酶的活性显著降低。总的来说,这项研究的结果表明,不同 rUGTs(每 pmol 蛋白质)的特异性活性(每 pmol)差异很大且不稳定,这应在 f 缩放中加以考虑。

相似文献

1
Comparison of Relative Activity versus Relative Expression Factors (RAF versus REF) in Predicting Glucuronidation Mediated Drug Clearance Using Recombinant UGTs.使用重组 UGT 预测葡萄糖醛酸化介导的药物清除率时,相对活性与相对表达因子(RAF 与 REF)的比较。
Pharm Res. 2024 Aug;41(8):1621-1630. doi: 10.1007/s11095-024-03750-x. Epub 2024 Aug 6.
2
Characterization of the Ontogeny of Hepatic UDP-Glucuronosyltransferase Enzymes Based on Glucuronidation Activity Measured in Human Liver Microsomes.基于人肝微粒体中葡萄糖醛酸化活性测定的肝 UDP-葡萄糖醛酸转移酶酶的个体发生特征。
J Clin Pharmacol. 2019 Sep;59 Suppl 1:S42-S55. doi: 10.1002/jcph.1493.
3
Human UDP-glucuronosyltransferase isoforms involved in bisphenol A glucuronidation.参与双酚A葡萄糖醛酸化的人类UDP-葡萄糖醛酸基转移酶同工型。
Chemosphere. 2008 Dec;74(1):33-6. doi: 10.1016/j.chemosphere.2008.09.053. Epub 2008 Nov 5.
4
Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10.曲格列酮在人肝脏和肠道微粒体中的葡萄糖醛酸化:UGT1A8和UGT1A10的高催化活性。
Drug Metab Dispos. 2002 Dec;30(12):1462-9. doi: 10.1124/dmd.30.12.1462.
5
Glucuronidation of edaravone by human liver and kidney microsomes: biphasic kinetics and identification of UGT1A9 as the major UDP-glucuronosyltransferase isoform.依达拉奉在人肝微粒体和肾微粒体中的葡萄糖醛酸化:双相动力学及 UGT1A9 为主要的 UDP-葡萄糖醛酸基转移酶同工酶的鉴定。
Drug Metab Dispos. 2012 Apr;40(4):734-41. doi: 10.1124/dmd.111.043356. Epub 2012 Jan 11.
6
Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform.多巴胺的区域选择性葡萄糖醛酸化:显著的物种差异及人尿苷二磷酸葡萄糖醛酸基转移酶同工型的鉴定
Drug Metab Dispos. 2005 Mar;33(3):403-12. doi: 10.1124/dmd.104.002667. Epub 2004 Dec 17.
7
Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes.人组织微粒体和过表达的尿苷二磷酸葡萄糖醛酸基转移酶对苯并(a)芘-反式-7,8-二氢二醇葡萄糖醛酸化作用的表征
Cancer Res. 2002 Apr 1;62(7):1978-86.
8
Glucuronidation of mono(2-ethylhexyl) phthalate in humans: roles of hepatic and intestinal UDP-glucuronosyltransferases.邻苯二甲酸单(2-乙基己基)酯在人体中的葡糖醛酸化:肝和肠 UDP-葡糖醛酸基转移酶的作用。
Arch Toxicol. 2017 Feb;91(2):689-698. doi: 10.1007/s00204-016-1708-9. Epub 2016 Apr 12.
9
Characterization of hepatic and intestinal glucuronidation of magnolol: application of the relative activity factor approach to decipher the contributions of multiple UDP-glucuronosyltransferase isoforms.鉴定厚朴酚在肝脏和肠道中的葡萄糖醛酸化:相对活性因子法在解析多种 UDP-葡萄糖醛酸转移酶同工酶作用中的应用。
Drug Metab Dispos. 2012 Mar;40(3):529-38. doi: 10.1124/dmd.111.042192. Epub 2011 Dec 16.
10
Clotrimazole Identified as a Selective UGT2B4 Inhibitor Using Canagliflozin-2'--Glucuronide Formation as a Selective UGT2B4 Probe Reaction.克霉唑被鉴定为一种选择性 UGT2B4 抑制剂,使用坎格列净-2'-葡萄糖醛酸苷的形成作为选择性 UGT2B4 探针反应。
Drug Metab Dispos. 2024 Sep 16;52(10):1083-1093. doi: 10.1124/dmd.124.001812.

本文引用的文献

1
Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling.贝鲁替尼的群体药代动力学分析,为剂量调整和标签提供信息。
CPT Pharmacometrics Syst Pharmacol. 2023 Oct;12(10):1499-1510. doi: 10.1002/psp4.13028. Epub 2023 Aug 28.
2
Drug-drug interactions that alter the exposure of glucuronidated drugs: Scope, UDP-glucuronosyltransferase (UGT) enzyme selectivity, mechanisms (inhibition and induction), and clinical significance.药物-药物相互作用改变葡萄糖醛酸化药物的暴露:范围、尿苷二磷酸葡萄糖醛酸转移酶(UGT)酶选择性、机制(抑制和诱导)以及临床意义。
Pharmacol Ther. 2023 Aug;248:108459. doi: 10.1016/j.pharmthera.2023.108459. Epub 2023 May 30.
3
Intestinal Metabolism of Diclofenac by Polymorphic UGT2B17 Correlates with its Highly Variable Pharmacokinetics and Safety across Populations.
多态性 UGT2B17 对双氯芬酸的肠道代谢与其在人群中的高度可变药代动力学和安全性相关。
Clin Pharmacol Ther. 2023 Jul;114(1):161-172. doi: 10.1002/cpt.2907. Epub 2023 Apr 29.
4
Quantification of Accurate Composition and Total Abundance of Homologous Proteins by Conserved-Plus-Surrogate Peptide Approach: Quantification of UDP Glucuronosyltransferases in Human Tissues.通过保守加替代肽方法定量同源蛋白质的准确组成和总丰度:人组织中 UDP 葡萄糖醛酸基转移酶的定量。
Drug Metab Dispos. 2023 Mar;51(3):285-292. doi: 10.1124/dmd.122.001155. Epub 2022 Nov 29.
5
In silico prediction of UGT-mediated metabolism in drug-like molecules via graph neural network.通过图神经网络对类药物分子中UGT介导的代谢进行计算机模拟预测。
J Cheminform. 2022 Jul 8;14(1):46. doi: 10.1186/s13321-022-00626-3.
6
Intersystem Extrapolation Factors Are Substrate-Dependent for CYP3A4: Impact on Cytochrome P450 Reaction Phenotyping.对于 CYP3A4,体系外推因子是底物依赖性的:对细胞色素 P450 反应表型的影响。
Drug Metab Dispos. 2022 Mar;50(3):249-257. doi: 10.1124/dmd.121.000758. Epub 2021 Dec 13.
7
Vorinostat (SAHA) and Breast Cancer: An Overview.伏立诺他(SAHA)与乳腺癌:概述
Cancers (Basel). 2021 Sep 19;13(18):4700. doi: 10.3390/cancers13184700.
8
Characterization of Hepatic UDP-Glucuronosyltransferase Enzyme Abundance-Activity Correlations and Population Variability Using a Proteomics Approach and Comparison with Cytochrome P450 Enzymes.使用蛋白质组学方法表征肝脏UDP-葡萄糖醛酸转移酶的酶丰度-活性相关性及群体变异性,并与细胞色素P450酶进行比较。
Drug Metab Dispos. 2021 Sep;49(9):760-769. doi: 10.1124/dmd.121.000474. Epub 2021 Jun 29.
9
Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping.用于体外人药物和化学物质葡萄糖醛酸化表征及尿苷二磷酸葡萄糖醛酸基转移酶反应表型分析的循证策略。
Pharmacol Ther. 2021 Feb;218:107689. doi: 10.1016/j.pharmthera.2020.107689. Epub 2020 Sep 25.
10
Industrial Approach to Determine the Relative Contribution of Seven Major UGT Isoforms to Hepatic Glucuronidation.工业方法确定七种主要 UGT 同工酶对肝脏葡萄糖醛酸化的相对贡献。
J Pharm Sci. 2020 Jul;109(7):2309-2320. doi: 10.1016/j.xphs.2020.03.013. Epub 2020 Apr 12.